Screening and bioinformatic analyses of serum microRNAs in papillary thyroid carcinoma with lung metastases based on iodine-131 uptake capacity

XUE Yan-li,QIU Zhong-ling,SONG Hong-jun,LUO Quan-yong

2013-01-01

Abstract:Objective To compare the differences in serum miRNAs between papillary thyroid carcinoma(PTC)patients with 131I-avid lung metastases and those with non-131I-avid lung metastases,and to screen a serum miRNA relevant to 131I uptake in lung metastases from PTC.Methods We collected serum samples from 9 PTC patients with 131I-avid lung metastases(Group A)and 9 PTC patients with non-131I-avid lung metastases(Group B)respectively,and both groups were matched for age and sex,without history of other tumors.The serum miRNAs were profiled using miRNA chip technology and the difference between the two groups was compared.Bioinformatics analysis was performed to screen the core miRNAs.Results A total of 13 serum miRNAs with statistically significant differences were detected between Group A and Group B.Among them,5 miRNAs displayed high expression,and 8 miRNAs showed low expression in Group B.Bioinformatics analysis showed that serum miR-106a was the core miRNA.The miR-106a was involved in regulating 193 target genes,including MAPK1,MAP3K8,MAP3K3,MAP3K12,MAP3K5,MAP3K14,MAP3K2,MAPK11 and et al.Conclusions The serum miRNAs were significantly different between PTC patients with 131I-avid lung metastases and those with non-131I-avid lung metastases.The miR-106a,which was significantly increased in patients with non-131I-avid lung metastases,was the core miRNA.Serum miR-106a might be associated with lung metastases losing the function of 131I uptake.